Peptide Stacks & Regimens Studio
Precision multi-peptide research cycles engineered with separate physical lyophilized vials. Features interactive diluent stoichiometry, live U-100 syringe graduation visualizers, synchronized 7-day administration schedules, and 1-click complete kit fulfillment.
Peptide Stacking & Multi-Product Compatibility Studio
Evaluate whether multiple separate products are safe, synergistic, or contraindicated to run together in your research protocol. Search our catalog, discover verified compatible stacking partners, and generate synchronized co-administration protocols.
🔍 Search Peptides to Stack:
Type any compound name, target receptor, or biological indication to see stack options.
Peptides that can be safely stacked with CJC-1295 No DAC (Mod GRF 1-29)
CJC-1295 (GHRH agonist) stimulates the synthesis and transcription of Growth Hormone in pituitary somatotropes, while Ipamorelin (selective GHSR agonist) suppresses somatostatin and triggers the vesicular release pulse. Together they produce an amplified physiological GH pulse up to 5x higher than either alone.
Angiogenesis, granulation tissue formation, nitric oxide synthesis
Systemic cell migration, microvascular remodeling, scar tissue prevention
Glucose-dependent insulinotropic polypeptide + glucagon-like peptide-1 appetite & insulin modulation
Central satiety signaling, delayed gastric emptying, insulin sensitization
Triple incretin co-agonism with enhanced hepatic lipid oxidation and energy expenditure
Stimulates lipolysis in white adipose tissue and inhibits lipogenesis without altering IGF-1 or glycemic levels
Synergistic Multi-Pathway Amplification
The selected products exert complementary pharmacological actions across distinct receptor targets, producing therapeutic effects superior to either agent alone.
Optional fasted morning dose: CJC-1295 100 mcg + Ipamorelin 200 mcg
Primary dose 30 min before bed: CJC-1295 100 mcg + Ipamorelin 200 mcg (≥2h fasted)
5 days on, 2 days off (e.g., Monday through Friday on, weekends off) to preserve pituitary receptor sensitivity.
12 to 16 weeks on · 4 weeks washout period
CJC-1295 No DAC + Ipamorelin
CJC-1295 (GHRH agonist) stimulates the synthesis and transcription of Growth Hormone in pituitary somatotropes, while Ipamorelin (selective GHSR agonist) suppresses somatostatin and triggers the vesicular release pulse. Together they produce an amplified physiological GH pulse up to 5x higher than either alone.
Co-administer together 30 minutes before sleep on a strictly fasted stomach (≥2 hours after last meal) to avoid somatostatin release from carbohydrate/insulin spikes.
Prepare each compound in its own vial. Injections may be taken in the same time window into separate SubQ sites.
Synchronized Stoichiometry, Syringe Calibrator & Kit Builder
Live stoichiometric recalculations, syringe tick marks, and 1-click kit fulfillment for all 2 active vials in this regimen.
Dual-Channel Reconstitution & Stoichiometry Station
Independent volumetric stoichiometry, fluid graduation, and U-100 syringe barrel calibration for each constituent physical vial.
Interactive Syringe Calibration & Reconstitution Stoichiometry— CJC-1295 No DAC (Mod GRF 1-29)
Constituent Channel #1 of 2 (CJC-1295 No DAC (Mod GRF 1-29))
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
| Escalation Stage & Phase | Target Dose | U-100 Mark (3mg / 1.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| Phase 1: GHRH Receptor Calibration (Weeks 1–2) | 100 mcg daily | 3.3 Units(0.03 mL) | 1x Daily (Pre-Bed) | |
| Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg – 200 mcg daily | 3.3 Units(0.03 mL) | 1x to 2x Daily (AM Fasted / PM Pre-Bed) | |
| Phase 3: Washout & Receptor Reset (Weeks 11–12) | Observation Period | 0.0 Units(0.00 mL) | Zero dosing |
| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 50 mcg (Micro Initiation) | 0.025 mL | 2.5 Units 2.5 units (0.025 mL) on U-100 syringe |
| 100 mcg (Standard Target) | 0.050 mL | 5 Units 5.0 units (0.05 mL) on U-100 syringe |
| 200 mcg (High Output Target) | 0.10 mL | 10 Units 10.0 units (0.10 mL) on U-100 syringe |
Add 2.5 mL diluent slowly down the glass wall. Gently rotate the vial horizontally for 45 seconds until powder is completely clear. Do not vortex or agitate.
Never re-insert a needle into Vial B after drawing from Vial A. Doing so introduces cross-compound enzymes and permanently ruins lot purity.
Always use separate U-100 insulin syringes for each constituent compound. Ensure both syringes are labeled before administration.
Dispense constituent peptides into isolated in-vitro assay channels or separate analytical vessels to prevent unquantified cross-reactivity prior to scheduled observation.
Standard Operating Procedure (SOP): Multi-Peptide Stack Protocol
1. Pharmacodynamic Stacking Overview & Synergy Evaluation
The selected products exert complementary pharmacological actions across distinct receptor targets, producing therapeutic effects superior to either agent alone.
2. Multi-Vial Reconstitution Stoichiometry Station (2 Individual Vials)
| Vial # | Compound Name | Vial Mass | Diluent Vol | Concentration | Target Assay Dose | U-100 Syringe Draw |
|---|---|---|---|---|---|---|
| Vial #1 | CJC-1295 No DAC (Mod GRF 1-29) | 5 mg | 2.5 mL | 2 mg/mL | 100 mcg daily (or 100 mcg 1–3x daily with Ipamorelin) | 5.0 units (0.05 mL) |
| Vial #2 | Ipamorelin (GHRP Selective) | 10 mg | 2 mL | 5 mg/mL | 100 mcg – 300 mcg daily | 4.0 units (0.04 mL) |
3. Co-Administration Schedule & Timing Synchronization
Optional fasted morning dose: CJC-1295 100 mcg + Ipamorelin 200 mcg
Primary dose 30 min before bed: CJC-1295 100 mcg + Ipamorelin 200 mcg (≥2h fasted)
Weekly Rhythm: 5 days on, 2 days off (e.g., Monday through Friday on, weekends off) to preserve pituitary receptor sensitivity.
Cycle Length: 12 to 16 weeks
Mandatory Washout: 4 weeks washout period
- Strict Syringe Separation: Maintain separate sterile U-100 syringes for each individual reconstituted vial. NEVER draw multiple peptide solutions into a single syringe.
- Precipitation Guardrail: Differing pH buffers (e.g. alkaline copper peptides vs acidic peptide solutions) will precipitate out of solution and aggregate if co-mingled in liquid phase.
- Vial Septum Access Rotation: Rotate cannula puncture positions across the rubber vial septum (avoid repeated punctures at identical coordinates to preserve septum integrity and prevent elastomeric coring).
- Refrigerated Storage: Store reconstituted vials at 2°C – 8°C (36°F – 46°F) protected from direct UV light.